Astrazeneca

(Image: Getty/Bedo)

The most read stories in March

By Staff Reporter

After the M&A excitement that began the year, the developments in March were a mixture of long-running events, such as the sartan manufacturing issues, breakthrough research and regulatory struggles.

(Image: Getty/Medley of Photography)

AstraZeneca cuts 94 jobs from UK campus

By Ben Hargreaves

The Anglo-Swedish company will cut the positions from the site by 2020, with a consultation on the process initiated yesterday, a workers union claimed.

(Image: Getty/Bong Hyunjung)

MedImmune will cease to exist after 30 years

By Ben Hargreaves

In full-year financials, AstraZeneca announced that its R&D arm, MedImmune, will be absorbed into the overall company as it restructures its R&D units into specific therapy areas.

Pharma appointments create controversy

Hired and Retired: Controversies at the top

By Ben Hargreaves

The new year has led to a new look to executive boards across the pharma industry, but the movement has arrived with a degree of intrigue in some cases.